Interim Report Q3 2021

22 October, 2021

Sobi publishes report for the third quarter 2021

Read full report

Highlights from the quarter

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the third quarter 2021. Total revenue amounted to SEK 3,761 M, a 29 per cent growth at CER compared with the same period 2020. EBITA was SEK 1,166 M, resulting in an EBITA margin of 31 per cent.

July – September

Total revenue SEK 3,761 M (2,970), +27 per cent, +29 per cent at constant exchange rates (CER)
Haematology revenue SEK 2,291 M (2,147), +9 per cent at CER of which Elocta® SEK 1,035 M (1,115), -6 per cent at CER, Alprolix® SEK 430 M (435), unchanged at CER, and Doptelet® SEK 400 M (145), +187 per cent at CER
Immunology revenue SEK 1,144 M (619), +89 per cent at CER of which Kineret® SEK 516 M (463), +13 per cent at CER, Synagis® SEK 374 M (46), +769 per cent at CER, and Gamifant® SEK 255 M (110), +139 per cent at CER
EBITA¹ SEK 1,166 M (933), EBITA margin¹ 31 per cent (31)
Earnings per share (EPS) before dilution SEK 1.60 (0.94)
Cash flow from operating activities SEK 257 M (381)

January – September

Total revenue SEK 10,633 M (10,680), unchanged and +7 per cent at CER
Haematology revenue SEK 6,294 M (6,578), +1 per cent at CER of which Elocta SEK 2,896 M (3,514), -14 per cent at CER, Alprolix SEK 1,281 M (1,286), +4 per cent at CER, and Doptelet SEK 810 M (396), +126 per cent at CER
Immunology revenue SEK 3,450 M (3,133), +21 per cent at CER, of which Kineret SEK 1,608 M (1,493), +16 per cent at CER, Synagis SEK 1,286 M (1,294), +13 per cent at CER, and Gamifant SEK 556 M (346), +78 per cent at CER
EBITA¹ SEK 3,572 M (4,124), EBITA margin¹ 34 per cent (39)
EPS before dilution SEK 4.87 (5.92)
Cash flow from operating activities SEK 3,349 M (4,209)

Significant events after the reporting period

Aspaveli® (pegcetacoplan) for PNH: positive CHMP opinion in the EU

Financial outlook 2021 – refined

Revenue for the full year 2021 is expected to be in the range of SEK 14,500–15,000 M
EBITA margin is expected to be in the range of 33–35 per cent of revenue

Guido Oelkers, CEO and President:

“We saw continued growth and pipeline progress in the third quarter of 2021, and it is satisfying to see that results are confirming our strategic direction. Overall, our two main business areas are in solid shape and they progressed as expected.”

Financial Summary

	Q3	Q3		Jan-Sep	Jan-Sep		Full-year
SEK M	2021	2020	Change	2021	2020	Change	2020
Total revenue	3,761	2,970	27%	10,633	10,680	0%	15,261
Gross profit	2,802	2,339	20%	8,165	8,318	-2%	12,036
Gross margin¹	75%	79%		77%	78%		79%
EBITA¹	1,166	933	25%	3,572	4,124	-13%	6,700
EBITA adjusted^1,2	1,166	933	25%	3,572	4,124	-13%	6,301
EBITA margin¹	31%	31%		34%	39%		44%
EBITA margin adjusted^1,2	31%	31%		34%	39%		41%
Profit for the period	473	278	70%	1,438	1,743	-18%	3,245
Earnings per share, before dilution, SEK	1.60	0.94	70%	4.87	5.92	-18%	11.01
Earnings per share, before dilution, SEK adjusted^1,2,3	1.60	0.94	70%	4.87	5.92	-18%	9.66

¹Alternative Performance Measures (APMs). ²EBITA in 2020 excluding non-recurring items; other operating income related to the reversal of the CVR liability of SEK 399 M. ³EPS in full-year 2020 excluding the reversal of the CVR liability of SEK 399 M.

Contacts

Thomas Kudsk Larsen
Head of Communication and Investor Relations

Maria Kruse
Director of Communication and Investor Relations

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

Sobi™

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology, and specialty indications. Sobi employs approximately 1,500 people across Europe, North America, the Middle East, Russia, and Asia. In 2020, Sobi’s revenues amounted to SEK 15.3 billion. Sobi’s share (STO: SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.

See all press releases

See all financial reports

© Swedish Orphan Biovitrum AB (publ) Reg. no. 556038-9321